Replies to post #392400 on Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

This post should be stickied... excellent job CMC!

some excerpts follow, but the whole post should be read.

Tecovirimat is also a good example of what happens after NIAID takes a drug successfully to a Phase 2A. The company that owns the drug completes the rest of the development through FDA approval/authorization.

In the case of B-AV, Leo will be in the driver's seat, not only because "B" will have the data. thanks to NIAID. but also because the potential partner will know that after a successful Phase 3 and FDA approval/authorization: the U.S. gov't, as well as other gov'ts will be the first customers in line placing orders in the hundreds of millions for B-AV (broad spectrum), B-COVID, Monkeypox or any other family of viruses that threaten the U.S. and other populations around the world.

It is very important that NIAID has latched onto Brilacidin and after 2.5 years is still investigating the scope of its antiviral attributes. NIAID's is responsible for finding and initially developing vaccines and therapeutics that address viral pathogens that are threatening or could threaten the U.S. population. NIAID is the playmaker, who coordinates and collaborates with other similarly concerned U.S. gov't agencies and gov't-funded, private research institutions.

NIAID has a high-degree of interest in Brilacidin and I can't wait to see which direction they move in. Will it be "B" as a COVID prophylactic, broad-spectrum antiviral or possibly something involving mokeypox?

One thing's for sure, the antiviral sector is Brilacidin's most lucrative area ($67B) and IPIX is in collaboration with an agency of the U.S. government (NIAID) that is extremely interested in investigating "B" ,as an antiviral, for all that it can do. AT NO CHARGE TO IPIX.

[leavetheguntakethecannolis]

Fantastic post and analysis CMC. Keep up the good work!

[MackG]

CMC, thanks for helping to keep in focus the tremendous investment opportunity with IPIX at this juncture. I especially liked this part of your post: "One thing's for sure, the antiviral sector is Brilacidin's most lucrative area ($67B) and IPIX is in collaboration with an agency of the U.S. government (NIAID) that is extremely interested in investigating "B" ,as an antiviral, for all that it can do. AT NO CHARGE TO IPIX.
NIAID, operating in its own interest with Brilacidin, could be a very, very, financially rewarding collaboration for IPIX. This is what NIAID's drug development track record suggest.

[CallMeCrazy]

NIAID To Try "B" As Broad- Spectrum Anti-Coronavirus Prophylactic
This is my opinion based on a substantial amount of evidence.

In 2020, George Mason University reported in their testing of Brilacidin:
" Brilacidin’s ability to disrupt viral integrity and block viral entry indicates it has the added potential to prevent infection, upon appropriate formulation, as a prophylactic."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169609082

"University of Arizona and University of California-San Francisco scientists characterized the antiviral activity of Brilacidin against multiple endemic human coronaviruses (HCoVs), including HCoV-OC43, HCoV-229E, HCoV-NL63, and SARS-CoV-2, in human cell lines...
Mechanistic studies revealed Brilacidin exerts antiviral activity by interfering with viral attachment to host cells by binding to heparan sulfate proteoglycans (HSPGs). HSPGs are important co-receptors through which different viruses gain entry into host cells, thus providing an attractive target for the development of broad-spectrum antivirals. Beyond exhibiting this blocking property, Brilacidin was also shown to target viral proteins directly, acting through a virucidal property. This dual antiviral mechanism of action suggests Brilacidin may be well-suited for prophylactic development and less likely to be subject to drug resistance.
http://www.ipharminc.com/press-release/2022/3/15/innovation-pharmaceuticals-announces-publication-of-peer-review-article-in-the-journal-of-medical-virology-on-anti-coronavirus-properties-of-brilacidin

And completing the trifecta:

"Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2.

Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested..."
http://www.ipharminc.com/press-release/2022/6/23/innovation-pharmaceuticals-reports-brilacidin-inhibits-omicron-delta-gamma-and-alpha-sars-cov-2-variants-based-on-in-vitro-testing-by-nihniaid-sponsored-and-rutgers-university-researchers

Even Brilacidin's COVID-19, phase 2, that many considered a failure, provided support for Brilacidin's potential as a broad-based, anti-coronavirus prophylactic.

"If a patient started study treatment within fewer than 7 days of onset of COVID-19 symptoms, patients in the Brilacidin 5-dose group achieved sustained recovery more quickly compared to the pooled placebo group (p=0.03). For this patient population, early treatment with Brilacidin from onset of symptoms appeared to have a potential positive impact on time to sustained recovery (the study’s primary endpoint), suggesting cases that can be treated close to initial onset of disease may be an attractive population to target for Brilacidin treatment"
https://www.ipharminc.com/press-release/2022/3/7/innovation-pharmaceuticals-reports-additional-findings-based-on-review-of-brilacidin-phase-2-covid-19-trial-results-and-compassionate-use-cases

The potential for Brilacidin as a broad-spectrum, anti-coronavirus prophylactic has been demonstrated in three university's testing (in vitro) and one COVID-19 phase 2 study (in vivo).

The "Omicron" variant of COVID-19 is still a pathogen of major concern for NIAID.

"The Omicron was first detected in November 2021 and has become the most dominant strain of COVID-19...The majority of people likely infected with the omicron variant of COVID-19 were unaware, according to a study from a medical center in Los Angeles, Calif...Our study findings add to evidence that undiagnosed infections can increase transmission of the virus."
https://www.npr.org/2022/08/19/1118402942/omicron-variant-unaware-covid-research-study?fbclid=IwAR0592RVoGEQ9A4qGiZvhLDi6oDYUyKMKNPLv8F9x0GAOQwkI2-U9YAlny4

And just in case you were thinking there's no more "gold in them-thar COVID hills:

"According to the latest market intelligence research report by InsightAce
Analytic, the global COVID-19 Therapeutics market size was valued at US$ 10.2
Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record
a promising CAGR of 10.7% from 2021 to 2030."
https://www.bloomberg.com/press-releases/2022-01-18/global-covid-19-therapeutics-market-worth-14-6-billion-by-2022-exclusive-report-by-insightace-analytic

Testing at 3 universities (in vitro) and B's COVID P-2 (in vivo), all indicate that B-AV's "blocking" attribute indicate it is well-suited for the role of broad-spectrum, anti-coronavirus prophylactic. B's COVID P-2 went a long way in helping researchers to see that B's role, at least insofar as COVID is concerned, is probably preventing COVID from entering the body and NOT eradicating COVID after it has built-up a strong position in the body.

The data suggest that prophylactic B-COVID will keep the virus/variant out of the body and that COVID may not be able to created a "Trojan Horse" (mutation) to get around it.

I believe NIAID will, ultimately, conduct many clinical trials, researching Brilacidin's antiviral attributes against many viral families, but, given the immediate threat still posed by COVID/Omicron and data suggesting B's ability to inhibit this virus, I think NIAID will conduct this B-COVID prophylactic trial first.

After approval and in short order, I believe B-COVID could become a billion-dollar indication practically overnight, based only on worldwide sales to governments, who will stockpile and distribute.

Message in reply to:
NIAID has a high-degree of interest in Brilacidin and I can't wait to see which direction they move in. Will it be "B" as a COVID prophylactic, broad-spectrum antiviral or possibly something involving monkeypox?

[loanranger]

"This NIAID Developed Drug Had 2021/Sales of $125M"
Updating through 6/30/22:
https://investor.siga.com/node/14416/html